Catalyzing the critical path initiative: FDA's progress in drug development activities

Citations Over TimeTop 1% of 2015 papers

Abstract

The US Food and Drug Administration (FDA) has directed considerable effort towards modernizing its regulatory processes over the past decade to address the challenges in the drug development sector. Through partnerships and input from stakeholders, multiple initiatives are under way, many projects have been launched, several have resulted in tangible results, and many are ongoing and under discussion. We are learning that collaborative efforts can better inform and leverage existing knowledge, that the challenges of data sharing and intellectual property can be overcome, and that there is wide interest in partnering to address key public health regulatory science issues. It is crucial that we continue to build on these initial efforts to facilitate drug development.

Related Papers

• → Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016(2017)32 cited
• → Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy(2019)21 cited
• → U.S. Food and Drug Administration—A Science-Based Regulatory Agency(2001)
• → Information to improve public perceptions of the food and drug administration (FDA’s) tobacco regulatory role(2020)
• → NIH–FDA Effort Focuses on Tobacco Research(2013)